Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Justifies Steep Prices, Plans Fancy Footwork In The Era Of Cures

Executive Summary

BioMarin CMO Geoff Nichol envisions "fancy footwork" in future payer negotiations for groundbreaking hemophilia therapy, during a discussion on value at the 2018 Biotech Showcase meeting, held in conjunction with the J.P. Morgan conference.

You may also be interested in...



Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

The First US Gene Therapy Maker Innovates On Pricing And Reimbursement

Spark priced the gene therapy Luxturna for inherited blindness at $850,000 for treatment of both eyes, below the $1m price some expected, and revealed pioneering market access plans. CEO Jeffrey Marrazzo and Harvard Pilgrim's Michael Sherman talked with Scrip about the details.

Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges

Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel